the SmallCapReview mailing list.
Aurinia Pharmaceuticals: A
late-stage biopharmaceutical company providing novel products specifically
engineered to treat a limited, targeted patient population suffering from
serious disease states for which there is a high unmet medical need.
Myriad Genetics: A
personalized medicine company, that focuses on the
development and marketing of predictive, personalized, and
prognostic medicine tests worldwide.
MYGN has a collaboration with AstraZeneca for the
development of an indication for BRACAnalysis CDx.
Where Small Cap Stocks Thrive Since
Caps Are Making Big Moves
Cap Relative Strength
Action In Select Small Caps Is Encouraging...
Small Caps Have Outperformed Apple For Three Months...
does this matter? Perhaps we should say why might it matter? Because when
small caps do well breadth tends to do well and when breadth does well the
market does well.
My Net Worth?
Like The Small Cap Rally
Russell 2000 Small Cap Index is up 10.5 percent to start 2019.
Caps Just Did Something They Haven't Done In Three Decades
start to the year since 1987.
Caps Should Outperform In 2019
Small Cap Techs On A Roll
Performing Small Caps Of 2018
Cap Indices Show Relative Strength In Both Directions
Your Zip Code Says About You
To Invest In Small Caps
Speed Of Correction In Small Caps
Cap Growth Pics For 2019
Small Caps To Buy In December
Small Caps That Look Like Bargains
has the potential to become a best in class medication and the first
approved treatment for LN in the U.S. and Europe."
on AUPH here...
has the deepest diagnostic pipeline across the disease spectrum."
on MYGN here...
Subscribers to our Free
newsletter will receive stock reports and news alerts for small-cap stocks
via email. You can sign-up
"A Primer In
is a leading destination for small-cap picks and news. The Purpose of
is to profile and bring awareness to companies with a market cap of
less than $1 billion, these small-cap stocks will primarily trade on the Nasdaq Small-Cap market. We also issue daily small cap
stocks to watch via various newswires. We will strive to bring you the
undiscovered, the undervalued, and the oversold.
does not give "buy" recommendations, price targets nor
suggest entry and exit points.
"A Look at Small Cap Stocks that may no longer be Small Caps"